Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

Stephen D Skaper


Stephen D Skaper

University of Padua, Italy

Biography

Stephen D. Skaper received a PhD in biochemistry from the University of South Dakota and Laurea in chemistry from the University of Padua, Italy. He is currently Adjunct Professor in the Department of Pharmaceutical and Pharmacological Sciences (section on Pharmacology and Anesthesiology) at the University of Padua. From 1998-2008 he was a Senior Group Leader for Neurodegeneration Research, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, United Kingdom. Prior to that he held academic research positions in the Department of Biology at the University of California, San Diego. Dr. Skaper has authored/co-authored over 300 research papers, book chapters and monographs, as well as having guest-edited six journal thematic issues and a volume of Methods in Molecular Biology on neurotrophic factors. He is Editor-in-Chief of CNS & Neurological Disorders Drug Targets, the Associate Editor of the American Journal of Neuroprotection and Neuroregeneration, and a Councillor of the International Association of Neurorestoratology. His research interests focus on the role of immune cells and their interactions in neuroinflammation, in particular with regards to neuropathic pain and autoimmune demyelinating diseases like multiple sclerosis, and the development of therapeutic strategies based on natural molecules. He is a member of Sigma I, Phi Lambda Upsilon, Alpha Chi Sigma, the Society for Neuroscience and the International Society of Cerebral Blood Flow and Metabolism. 

Abstract

Abstract : Co-ultramicronized palmitoylethanolamide/luteolin facilitates oligodendrocyte precursor cell development and improves outcome in experimental autoimmune encephalomyelitis